EGFR + NSCLC Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment
Explore our latest breakthroughs in EGFR + NSCLC research. Learn more about our innovative pipeline today! @ EGFR + NSCLC Pipeline Outlook
Key Takeaways from the EGFR + NSCLC Pipeline Report
In July 2025, ETOP IBCSG Partners Foundation announced a primary objective of the trial is to assess the efficacy of amivantamab and bevacizumab added to continued treatment with the third-generation EGFR-TKI lazertinib, in patients with EGFR-mutant advanced NSCLC, who have been previously treated with a third-generation EGFR-TKI in order to provide data on treatment effect and sample size required for a future phase III trial.
In June 2025, BlossomHill Therapeutics conducted a study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and/or human epidermal growth factor receptor (HER2) mutations. The study drug, BH-30643 capsules, will be self-administered by mouth twice daily in 21-day cycles.
In June 2025, Merck Sharp & Dohme LLC organized a study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs).
DelveInsight's EGFR + NSCLC pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for EGFR + NSCLC treatment.
The leading EGFR + NSCLC Companies such as Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics and others.
Promising EGFR+NSCLC Pipeline Therapies such as IN10018, Furmonertinib, Oral S-1 + Oral Osimertinib, YH25448, JS111 capsules (AP-L1898), Osimertinib, Gefitinib, RC108, Sunvozertinib, and others.
Stay informed about the cutting-edge advancements in EGFR + NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ EGFR + NSCLC Clinical Trials Assessment
EGFR + NSCLC Emerging Drugs Profile
CLN-081 is a novel irreversible Epidermal Growth Factor Receptor (EFGR) inhibitor. It is administered through oral route, and is developed by Cullinan Oncology. The drug is being developed in association with Taiho Pharmaceuticals. The drug is currently being investigated in the Phase III stage of development for the treatment of EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC).
BPI-361175: Betta Pharmaceuticals
BPI-361175 is a novel, oral, highly potent and selective 4th generation EGFR inhibitor developed by Betta Pharmaceutical Co., Ltd. The new chemical entity targets EGFR C797S mutation and other EGFR related mutations that are resistant to 3rd generation EGFR TKI in non-small cell lung cancer (NSCLC) and other solid tumors. It shows excellent inhibitory effect and selectivity in vitro assay and exhibits significant anti-tumor activity in a variety of xenograft models harboring EGFR C797S or other related mutations. The IND application of BPI-361175 has been approved by NMPA. Currently, the drug is the Phase I/II stage of its development for the treatment of Non-small Cell Lung Cancer.
G1T38: G1 Therapeutics
G1T38 is an investigational, oral CDK4/6 inhibitor designed to be used along with other targeted therapies for various oncology indications. G1 Therapeutics has entered a clinical trial collaboration to assess its G1T38 in combination with AstraZeneca's Tagrisso (osimertinib) in a Phase Ib/II clinical trial to treat patients suffering from EGFR mutation-positive non-small cell lung cancer (NSCLC). Currently, the drug is being evaluated in the Phase I/II stage in combination with osimertinib in patients with EGFR mutation-positive metastatic non-small cell lung cancer.
JANX008: Janux Therapeutics
JANX008, is a TRACTr that targets Epidermal Growth Factor Receptor (EGFR), and is being developed by Janux Therapeutics for the treatment of various solid tumors including non-small cell lung cancer. According to preclinical studies, JANX008 showed potent cleavage dependent anti-tumor activity, with limited toxicities in healthy tissues or CRS. JANX008, is currently being evaluated in phase I clinical trial for the treatment of various solid tumors.
The EGFR + NSCLC Pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of EGFR + NSCLC with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for EGFR + NSCLC Treatment.
EGFR + NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
EGFR + NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the EGFR + NSCLC market.
Learn more about EGFR + NSCLC Drugs opportunities in our groundbreaking EGFR + NSCLC research and development projects @ EGFR + NSCLC Unmet Needs
EGFR + NSCLC Companies
Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics and others.
EGFR Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
EGFR + NSCLC Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Discover the latest advancements in EGFR + NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ EGFR + NSCLC Market Drivers and Barriers, and Future Perspectives
Scope of the EGFR + NSCLC Pipeline Report
Coverage- Global
EGFR + NSCLC Companies- Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics and others.
EGFR+NSCLC Pipeline Therapies- IN10018, Furmonertinib, Oral S-1 + Oral Osimertinib, YH25448, JS111 capsules (AP-L1898), Osimertinib, Gefitinib, RC108, Sunvozertinib, and others.
EGFR + NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
EGFR + NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of EGFR + NSCLC Pipeline on our website @ EGFR + NSCLC Emerging Drugs and Companies
Table of Contents
Introduction
Executive Summary
EGFR Non-Small Cell Lung Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
EGFR Non-Small Cell Lung Cancer – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
CLN-081: Cullinan Oncology
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
BPI-361175: Betta Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Products
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Unmet Needs
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Market Drivers and Barriers
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Future Perspectives and Conclusion
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Analyst Views
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
4 hours ago
- Globe and Mail
Coinbase Q2 Earnings and Revenues Miss Estimates, Volumes Rise Y/Y
Coinbase Global, Inc. COIN reported second-quarter 2025 net operating earnings per share of 12 cents, which missed the Zacks Consensus Estimate by 89.9%. The bottom line decreased 88.8% year over year. COIN witnessed lower crypto volatility and lower transaction revenue in the quarter while operating expenses increased. Operational Update Total trading volume increased 4.9% year over year to 237 million in the reported quarter. The Zacks Consensus Estimate was pegged at 235 million. Total revenues of $1.5 billion missed the Zacks Consensus Estimate by 0.5%. The top line, however, increased 3.2% year over year on higher transaction revenues, subscription and services revenues and other revenues. Total transaction revenues decreased 2.1% year over year to $764.3 million in the quarter. The decline was due to lower consumer transaction revenues as well as institutional transaction revenues. The Zacks Consensus Estimate was pegged at $795 million. Total subscription and services revenues increased 9.5% year over year to $655.8 million in the reported quarter. The growth was driven by higher stablecoin revenues. The Zacks Consensus Estimate was pegged at $692 million. Total operating expenses increased 37.5% to $1.5 billion in the quarter due to higher transaction expense, technology and development, sales and marketing and general and administrative expenses as well as other operating expense. Adjusted EBITDA was $512 million in the reported quarter, which fell 3.2% from the year-ago quarter. Financial Update Coinbase exited the second quarter with cash and cash equivalents of $7.5 billion as of June 30, 2025, down 11.8% from 2024-end. As of June 30, 2025, long-term debt increased 62.6% from 2024-end to $2.9 billion. Shareholders' equity was $12.1 billion at second-quarter 2025-end, up 17.7% from 2024-end. Net cash provided by operating activities was $145.7 million in first-half 2025, a drop of 83.7% year over year. Q3 2025 Outlook Coinbase expects subscription and services revenues to be in the range of $665-$745 million, driven primarily by higher average crypto prices and stablecoin revenues. Transaction expenses are expected to be in the mid-teens as a percent of net revenues. Coinbase expects technology and development and general and administrative expenses to be in the range of $800-$850 million, driven by headcount growth to support international expansion, new product initiatives and strengthening of customer support & security functions. Coinbase expects sales and marketing expenses to increase quarter over quarter to $190-$290 million, driven by potential variability in performance marketing and customer USDC balances in Coinbase products, which drive USDC reward. Zacks Rank COIN currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Peer Releases American Express Company AXP reported second-quarter 2025 earnings per share (EPS) of $4.08, which beat the Zacks Consensus Estimate by 5.7%. The bottom line climbed 17% year over year. Total revenues net of interest expense amounted to $17.9 billion, which outpaced the Zacks Consensus Estimate by 1%. The top line improved 9% year over year in the quarter under review. Network volumes of $472 billion rose 7% year over year in the second quarter, driven by higher U.S. consumer spending. Total interest income of $6.3 billion increased 8% year over year and beat the consensus mark by 0.4%. American Express still anticipates revenues to increase between 8% and 10% in 2025 from the 2024 level of $65.9 billion. Management expects EPS in the range of $15-$15.50, the midpoint of which indicates an improvement of 8.9% from the 2024 level of $14.01. Bread Financial Holdings ' BFH operating income of $3.14 per share for the second quarter of 2025 beat the Zacks Consensus Estimate by 69.7%. The bottom line improved 18% year over year. Revenues decreased 1.1% year over year to $929 million. The top line also missed the consensus estimate by 0.9%. Credit sales of $6.8 billion increased 4%, driven by new partner growth and increased general-purpose spending. Our estimate was $6.6 billion. Average loans of $17.7 billion decreased 1%. Management estimates average receivables to be flat to slightly down from 2024. It expects average credit card and other loans to be flat to slightly down from the 2024 level. Total revenues are estimated to be flat year over year. The net loss rate is guided in the range of 7.8-7.9%. Virtu Financial 's VIRT second-quarter operating income of $1.53 per share for the second quarter of 2025 beat the Zacks Consensus Estimate by 0.8%. The bottom line improved 84.3% year over year. Revenues increased 47.5% year over year to $929 million. The top line also beat the consensus estimate by 9.4%. Adjusted EBITDA increased 69.8% to $369.4 million. Adjusted EBITDA margin of 65.1% expanded 860 bps year over year. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report American Express Company (AXP): Free Stock Analysis Report Virtu Financial, Inc. (VIRT): Free Stock Analysis Report Coinbase Global, Inc. (COIN): Free Stock Analysis Report Bread Financial Holdings, Inc. (BFH): Free Stock Analysis Report
Globe and Mail
4 hours ago
- Globe and Mail
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and AbbVie (ABBV)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY – Research Report) and AbbVie (ABBV – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Eli Lilly & Co (LLY) TD Cowen analyst Steve Scala maintained a Buy rating on Eli Lilly & Co today and set a price target of $960.00. The company's shares closed last Thursday at $763.28. According to Scala is a 4-star analyst with an average return of 6.7% and a 60.4% success rate. Scala covers the Healthcare sector, focusing on stocks such as Elanco Animal Health, GlaxoSmithKline, and Merck & Company. ;'> The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $1028.80 average price target, which is a 37.7% upside from current levels. In a report issued on July 17, TR | OpenAI – 4o also upgraded the stock to Buy with a $885.00 price target. AbbVie (ABBV) In a report released today, Matt Phipps from William Blair maintained a Buy rating on AbbVie. The company's shares closed last Thursday at $194.50. According to Phipps has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.6% and a 41.1% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Janux Therapeutics Inc, and Vertex Pharmaceuticals. ;'> Currently, the analyst consensus on AbbVie is a Moderate Buy with an average price target of $212.46, which is a 7.8% upside from current levels. In a report issued on July 16, TR | OpenAI – 4o also upgraded the stock to Buy with a $206.00 price target.
Globe and Mail
4 hours ago
- Globe and Mail
Prediction: Nvidia Stock Will Soar in the Second Half of 2025, Thanks to This Incredible News From Microsoft and Meta Platforms
Key Points Artificial intelligence (AI) is the driving force behind Nvidia's blistering growth, but investors have been wary about the future of AI. Meta Platforms and Microsoft just reported blockbuster results, which illustrate the staying power of AI. There's another catalyst that could fuel Nvidia's run in the second half of the year. 10 stocks we like better than Nvidia › Nvidia (NASDAQ: NVDA) has been the poster child for the AI revolution, with the stock on a marathon that has increased its stock price by more than 1,000% since the dawn of artificial intelligence (AI) in early 2023. In recent months, however, investors have been more circumspect, plagued by a moratorium on AI chip sales to China and the potential impact of broad-based tariffs on the economic landscape. Furthermore, the ebbs and flows of AI adoption have some investors concerned that the low-hanging fruit has been picked and the AI revolution will stall. Experts generally agree that the adoption of AI, in some form or fashion, will continue well into the next decade, but investors have been seeking reassurance. Two of Nvidia's largest customers released their respective quarterly financial reports after the market close on Wednesday. Meta Platforms (NASDAQ: META) and Microsoft (NASDAQ: MSFT) each reported blockbuster results, providing compelling evidence that the AI revolution is on track. The results speak for themselves Nvidia is scheduled to report the results of its fiscal 2026 second quarter (ended July 27) after the market close on Aug. 27. In the meantime, shareholders are looking for signs that the adoption of AI continues unfettered. Microsoft and Meta just provided exactly what investors were looking for. As the world's largest software company and second largest cloud infrastructure provider, Microsoft holds a unique place in the tech landscape. Furthermore, the company was quick to recognize the AI opportunity and pivoted to position itself accordingly. As a result, Microsoft has been reaping the rewards by providing a growing number of AI solutions to its vast customer base. During its fiscal 2025 fourth quarter (ended June 30), Microsoft generated revenue of $76.4 billion, rising 18% year over year. At the same time, its diluted earnings per share (EPS) of $3.65 climbed 24%. For context, analysts' consensus estimates were calling for revenue of $73.9 billion and EPS of $3.37, so Microsoft cleared both hurdles with ease. The results were fueled by Azure Cloud, as its growth rate accelerated to 39%, well ahead of the 34% expected by Wall Street. CEO Satya Nadella left no doubt about what was driving the results. "Cloud and AI is the driving force of business transformation across every industry and sector," he said. He went on to note that Azure Cloud surpassed $75 billion in revenue, fueled by strong demand for AI. Meta Platforms was also quick to recognize the opportunity afforded by AI, tapping into its wellspring of data to create its homegrown Llama AI models. The company has been spending heavily to capitalize on the AI windfall. In the second quarter, Meta delivered revenue of $47.5 billion, up 22% year over year, resulting in EPS of $7.14, a 38% increase. The consensus on Wall Street was revenue of $44.83 billion and EPS of $5.89, so Meta sailed past expectations with plenty of room to spare. In prepared remarks, CEO Mark Zuckerberg said, "The strong performance this quarter is largely thanks to AI unlocking greater efficiency and gains across our ads system," noting these systems drove "roughly 5% more ad conversions on Instagram and 3% on Facebook." It also wasn't surprising that AI is helping its social media platforms stay relevant. "AI is significantly improving our ability to show people content that they're going to find interesting and useful," Zuckerberg said. Nvidia's future looks bright It has been abundantly clear that Nvidia's meteoric rise is the direct result of the accelerating adoption of AI. Once known primarily for its gaming expertise, Nvidia's graphics processing units are now the gold standard for processing AI -- which is evident in its recent results. In Nvidia's fiscal 2026 first quarter, revenue of $44 billion surged 69% year over year, but that only tells part of the story. The company's data center segment, which includes AI chips, soared 69% to a record $39 billion, now accounting for 89% of Nvidia's considerable revenue. That helps explain why investors are so keen to understand whether AI has room to run. The future looks bright, as Nvidia is guiding for second-quarter revenue of $45 billion, or year-over-year growth of 50%. One of the biggest factors weighing on Nvidia in recent months is the Trump Administration's moratorium on H20 AI chip sales to China. CEO Jensen Huang recently announced that the company had filed an application that would permit Nvidia to resume selling those chips in China, and was assured that those licenses would be granted. The company took a $4.5 billion charge related to its H20 chips in the first quarter, but analysts estimate Nvidia could now generate additional sales of $15 billion in the back half of 2025. Furthermore, while Nvidia keeps its customer list under lock and key, analysts with Bloomberg and Barclays Research have read the tea leaves and concluded that Nvidia's four biggest customers -- responsible for nearly 53% of its revenue -- are: Microsoft: 15% Meta Platforms: 14% Alphabet: 12% Amazon: 11% The robust results generated by Microsoft and Meta Platforms offer clear and compelling evidence that the adoption of AI continues unfettered, and as two of Nvidia's biggest customers, that bodes well for the company's ongoing success. Finally, at just 31 times next year's expected earnings, Nvidia stock is reasonably priced. That's why I predict Nvidia stock will probably soar for the rest of 2025. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Danny Vena has positions in Alphabet, Amazon, Meta Platforms, Microsoft, and Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Meta Platforms, Microsoft, and Nvidia. The Motley Fool recommends Barclays Plc and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
